{
    "clinical_study": {
        "@rank": "124480", 
        "arm_group": [
            {
                "arm_group_label": "dose escalation part", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "expansion part", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this study are to determine the tolerability, safety, pharmacokinetics\n      (PK), pharmacodynamics (PD), and efficacy of oral ASP5878 in patients with solid tumors."
        }, 
        "brief_title": "An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This study consists of two parts.  In the dose-escalation part, ASP5878 is administered to\n      patients with solid tumors in an increasing dose manner, and the tolerability, safety,\n      pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of ASP5878 are evaluated in these\n      patients. In the expansion part, selected dose of ASP5878 is administered to patients with\n      limited types of carcinoma and safety, PK, PD and efficacy of ASP5878 are evaluated."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed solid tumor.\n\n          -  Patient must meet at least one of the following criteria in the judgment of the\n             investigator or sub-investigator:\n\n               -  Disease progression despite standard therapies\n\n               -  Progressive disease without any standard therapies established\n\n               -  Standard therapies are considered intolerable\n\n          -  Eastern Cooperative Oncology Group performance status 0 or 1.\n\n          -  Predicted life expectancy \u2265 12 weeks in the judgment of the investigator or\n             sub-investigator.\n\n        Exclusion Criteria:\n\n          -  Patient with \u2265 Grade 2 (CTCAE v 4.0-JCOG) persistent symptoms and objective findings\n             due to the toxicity attributable to prior treatment with antitumor effect (except\n             alopecia).\n\n          -  Patient who received a prior treatment intended for antitumor effect (medication,\n             surgery, radiotherapy, etc.) within 4 weeks prior to the planned first day of study\n             drug dosing (or patient who received mitomycin C or Nitrosourea within 6 weeks prior\n             to the planned first day of study drug dosing).\n\n          -  A major surgical procedure within 4 weeks prior to the planned first day of study\n             drug dosing or a surgical procedure is planned during the course of the study.\n\n          -  Patient who were treated with other investigational drug or medical device within 4\n             weeks prior to the planned first day of study drug dosing.\n\n          -  Patient who has a history of organ transplantation.\n\n          -  Patient with a brain metastasis with symptoms or requiring treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02038673", 
            "org_study_id": "5878-CL-0101"
        }, 
        "intervention": {
            "arm_group_label": [
                "dose escalation part", 
                "expansion part"
            ], 
            "description": "oral", 
            "intervention_name": "ASP5878", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "ASP5878", 
        "lastchanged_date": "January 15, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kanto", 
                    "country": "Japan"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors", 
        "overall_contact": {
            "email": "clintrialtrials_info@jp.astellas.com", 
            "last_name": "Clinical Development Administration Dept."
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety assessed by the incidence of adverse events, vital signs, laboratory tests and 12-lead ECGs", 
            "safety_issue": "No", 
            "time_frame": "up to Day 28 of each dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02038673"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Plasma concentration of unchanged ASP5878", 
                "safety_issue": "No", 
                "time_frame": "at 0.5-, 1-, 2-, 3-, 4-, 8-, 12-, 24-, 36-, 48- and 72-hour, and on Day8, Day15, Day 22, Day 27, Day28 after each dosing"
            }, 
            {
                "description": "RECIST version 1.1", 
                "measure": "Antitumor activity evaluated based on RECIST (Response Evaluation Criteria in Solid Tumors)", 
                "safety_issue": "No", 
                "time_frame": "On Day 28 of each cycle"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}